Targeted pill trial for aggressive pancreatic cancer ends early
NCT ID NCT05442749
Summary
This study tested whether a daily pill called niraparib could help control advanced pancreatic cancer that had spread and had specific genetic changes. The trial was designed for people who hadn't yet received chemotherapy for their metastatic cancer and had mutations in certain DNA repair genes. The study ended early with only 2 participants enrolled, so no conclusions could be drawn about the treatment's effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, 38043, France
-
Centre Léon Bérard
Lyon, 69373, France
Conditions
Explore the condition pages connected to this study.